Two-Year Efficacy And Safety Of Velaglucerase Alfa In Patients With Type 1 Gaucher Disease Switching From Imiglucerase: Phase III Trial HGT-GCB-039 And Extension
Publication
, Conference
Crombez, E; Kishnani, P; Turkia, HB; Gonzalez, D; Zimran, A; Kabra, M; Lukina, E; Giraldo, P; Kisinovsky, I; Bavdekar, A; Dridi, M-FB; Gupta, N
Published in: Molecular Genetics and Metabolism
February 2012
Duke Scholars
Published In
Molecular Genetics and Metabolism
DOI
ISSN
1096-7192
Publication Date
February 2012
Volume
105
Issue
2
Start / End Page
S25 / S26
Publisher
Elsevier BV
Related Subject Headings
- Genetics & Heredity
- 3202 Clinical sciences
- 3105 Genetics
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Crombez, E., Kishnani, P., Turkia, H. B., Gonzalez, D., Zimran, A., Kabra, M., … Gupta, N. (2012). Two-Year Efficacy And Safety Of Velaglucerase Alfa In Patients With Type 1 Gaucher Disease Switching From Imiglucerase: Phase III Trial HGT-GCB-039 And Extension. In Molecular Genetics and Metabolism (Vol. 105, pp. S25–S26). Elsevier BV. https://doi.org/10.1016/j.ymgme.2011.11.044
Crombez, Eric, Priya Kishnani, Hadhami Ben Turkia, Derlis Gonzalez, Ari Zimran, Madhulika Kabra, Elena Lukina, et al. “Two-Year Efficacy And Safety Of Velaglucerase Alfa In Patients With Type 1 Gaucher Disease Switching From Imiglucerase: Phase III Trial HGT-GCB-039 And Extension.” In Molecular Genetics and Metabolism, 105:S25–26. Elsevier BV, 2012. https://doi.org/10.1016/j.ymgme.2011.11.044.
Crombez E, Kishnani P, Turkia HB, Gonzalez D, Zimran A, Kabra M, et al. Two-Year Efficacy And Safety Of Velaglucerase Alfa In Patients With Type 1 Gaucher Disease Switching From Imiglucerase: Phase III Trial HGT-GCB-039 And Extension. In: Molecular Genetics and Metabolism. Elsevier BV; 2012. p. S25–6.
Crombez, Eric, et al. “Two-Year Efficacy And Safety Of Velaglucerase Alfa In Patients With Type 1 Gaucher Disease Switching From Imiglucerase: Phase III Trial HGT-GCB-039 And Extension.” Molecular Genetics and Metabolism, vol. 105, no. 2, Elsevier BV, 2012, pp. S25–26. Crossref, doi:10.1016/j.ymgme.2011.11.044.
Crombez E, Kishnani P, Turkia HB, Gonzalez D, Zimran A, Kabra M, Lukina E, Giraldo P, Kisinovsky I, Bavdekar A, Dridi M-FB, Gupta N. Two-Year Efficacy And Safety Of Velaglucerase Alfa In Patients With Type 1 Gaucher Disease Switching From Imiglucerase: Phase III Trial HGT-GCB-039 And Extension. Molecular Genetics and Metabolism. Elsevier BV; 2012. p. S25–S26.
Published In
Molecular Genetics and Metabolism
DOI
ISSN
1096-7192
Publication Date
February 2012
Volume
105
Issue
2
Start / End Page
S25 / S26
Publisher
Elsevier BV
Related Subject Headings
- Genetics & Heredity
- 3202 Clinical sciences
- 3105 Genetics
- 1103 Clinical Sciences